m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03006)
Name
Ketobemidone
Synonyms
Ketobemidone HCl; Ketobemidone hydrochloride; Ketobimedon hydrochloride; Ketogan (TN); Cliradon hydrochloride; LS-123062; SCHEMBL9706814; U9U6LTV80K; 1-Methyl-4-(m-hydroxyphenyl)piperidine-4-ethylketone hydrochloride; 1-Propanone, 1-(4-(m-hydroxyphenyl)-1-methyl-4-piperidyl)-, hydrochloride; 1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]propan-1-one hydrochloride(1:1); 5965-49-1; AC1L2YOJ; AC1Q5G7W; D08101; DTXSID00208327; EINECS 227-749-8; UNII-U9U6LTV80K
    Click to Show/Hide
Status
Phase 4
Structure
3D MOL
2D MOL
Formula
C15H22ClNO2
InChI
1S/C15H21NO2.C2H2O4/c1-3-14(18)15(7-9-16(2)10-8-15)12-5-4-6-13(17)11-12;3-1(4)2(5)6/h4-6,11,17H,3,7-10H2,1-2H3;(H,3,4)(H,5,6)
InChIKey
HYDFAZFVKRXNJX-UHFFFAOYSA-N
PubChem CID
80069
INTEDE Drug ID
DR0905
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cytochrome P450 2C8 (CYP2C8)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ketobemidone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Ketobemidone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ketobemidone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Ketobemidone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ketobemidone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ketobemidone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
YTH domain-containing protein 2 (YTHDC2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ketobemidone. The YTH domain-containing protein 2 (YTHDC2) has potential in affecting the response of Ketobemidone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). [1], [2]
References
Ref 1 Methylation of adenosine at the N(6) position post-transcriptionally regulates hepatic P450s expression. Biochem Pharmacol. 2020 Jan;171:113697. doi: 10.1016/j.bcp.2019.113697. Epub 2019 Nov 7.
Ref 2 Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96. doi: 10.1080/00498250500183181.